Probiotic Lactobacillus acidophilus FNCC 0051 Improves Pancreatic Histopathology in Streptozotocin-induced Type-1 Diabetes Mellitus Rats
Abstract
BACKGROUND: Intestinal microbial dysbiosis and its metabolites can affect the immune activity of intestinal mucosal cells, causing insulitis and pancreatic β-cell death. Probiotic Lactobacillus acidophilus plays an important role in reducing inflammatory cytokines, hence improves oxidative stress that affects pancreatic β-cell apoptosis. Current study examined the feature of pancreatic histopathology affected by the administration of probiotic L. acidophilus in rats with type-1 diabetes mellitus (DM) induced by streptozotocin (STZ).
METHODS: Twelve rats were induced by STZ at double dose of 50 mg/kgBB before administered with probiotic L. acidophilus at a dose of 1.5x10 8 or 1.5x10 9 CFU/mL/day, while other 4 rats were used as control. After 21 days of the L. acidophilus treatment, the average of fasting blood glucose (FBG) levels of rats were measured, then the pancreatic histopathology was assessed to evaluate the degree of insulitis in islet of Langerhans.
RESULTS: The induction of STZ had been succeeded to increase blood glucose levels, which indicate DM condition. The highest FBG level after 21 days of treatment was found in DM group with glucose level of 512±81.51 mg/dL. The administration of probiotic L. acidophilus during 21 days treatment at both dose 1.5x10 8 and 1.5x10 9 CFU/mL/day significantly improved pancreatic histopathology (p=0.04 and p=0.034, respectively), with significant decrease on insulitis scores compared to DM group.
CONCLUSION: The administration of L. acidophilus at both dose of 1.5x10 8 and 1.5x10 9 CFU/mL/day for 21 days can improve pancreatic histopathology of type-1 DM rats induced by STZ, therefore probiotic L. acidophilus may be potential as supplementation treatment for type-1 DM.
KEYWORDS: Lactobacillus acidophilus, pancreatic histopathology, streptozotocin, type-1 diabetes mellitus
Full Text:
PDFReferences
International Diabetes Federation. IDF Diabetes Atlas. 10th Ed. Brussels: International Diabetes Federation; 2021, article.
Ligita T, Wicking K, Francis K, Harvey N, Nurjannah I. How people living with diabetes in Indonesia learn about their disease: A grounded theory study. PLOS ONE. 2019; 14: 1-19, CrossRef.
Pulungan A. Increasing incidence of DM type 1 in Indonesia. Int J Pediatr Endocrinol. 2013; 2013(Suppl 1): O12, CrossRef.
Herawati E, Susanto A, Sihombing CN. Autoantibodies in diabetes mellitus. Mol Cell Biomed Sci. 2017; 1(2): 58-64, CrossRef.
Kartika R, Wibowo H. Impaired function of regulatory T cell in type 2 diabetes mellitus. Mol Cell Biomed Sci. 2020; 4(1): 1-9, CrossRef.
Lu J, Ma KL, Ruan XZ. Dysbiosis of gut microbiota contributes to the development of diabetes mellitus. Infect Microbes Diseases. 2019; 1(2): 43-8, CrossRef.
Roep BO, Thomaidou S, Tienhoven Rv, Zaldumbide A. Type 1 diabetes mellitus as a disease of the β-cell (do not blame the immune system?). Nat Rev Endocrinol. 2021; 17: 150-61, CrossRef.
In't Veld P. Insulitis in human type 1 diabetes: a comparison between patients and animal models. Semin Immunopathol. 2014; 36(5): 569-79, CrossRef.
In't Veld P. Insulitis in human type 1 diabetes: The quest for an elusive lesion. Islets. 2011; 3(4): 131-8, CrossRef.
Puddu A, Sanguineti R, Montecucco F, Viviani GL. Evidence for the gut microbiota short-chain fatty acids as key pathophysiological molecules improving diabetes. Mediators Inflamm. 2014; 2014: 162021, CrossRef.
Yadav H, Lee JH, Lloyd J, Walter P, Rane SG. Beneficial metabolic effects of a probiotic via butyrate-induced GLP-1 hormone secretion. J Biol Chem. 2013; 288(35): 25088-97, CrossRef.
Azad MAK, Sarker M, Li T, Yin J. Probiotic species in the modulation of gut microbiota: an overview. Biomed Res Int. 2018; 2018: 9478630, CrossRef.
Cristofori F, Dargenio VN, Dargenio C, Miniello VL, Barone M, Francavilla R. Anti-inflammatory and immunomodulatory effects of probiotics in gut inflammation: a door to the body. Front Immunol. 2021; 12: 578386, CrossRef.
Gomes AC, Bueno AA, de Souza RG, Mota JF. Gut microbiota, probiotics and diabetes. Nutr J. 2014; 13: 60, CrossRef.
Abdelazez A, Abdelmotaal H, Evivie SE, Melak S, Jia FF, Khoso MH, et al. Screening potential probiotic characteristics of Lactobacillus brevis strains in vitro and intervention effect on type I diabetes in vivo. Biomed Res Int. 2018; 2018: 7356173, CrossRef.
Wang-Fischer Y, Garyantes T. Improving the reliability and utility of streptozotocin-induced rat diabetic model. J Diabetes Res. 2018; 2018: 8054073, CrossRef.
Patterson E, Marques TM, O’Sullivan O, Fitzgerald P, Fitzgerald GF, Cotter PD, et al. Streptozotocin-induced type-1-diabetes disease onset in Sprague–Dawley rats is associated with an altered intestinal microbiota composition and decreased diversity. Microbiology. 2015; 161(1): 182-93, CrossRef.
Nopparat J, Nualla-ong A, Phongdara A. Ethanolic extracts of Pluchea indica (L.) leaf pretreatment attenuates cytokine-induced β-cell apoptosis in multiple low-dose streptozotocin-induced diabetic mice. PLOS ONE. 2019; 14: 1-19, CrossRef.
Mishra SP, Wang S, Nagpal R, Miller B, Singh R, Taraphder S, et al. Probiotics and prebiotics for the amelioration of type 1 diabetes: present and future perspectives. Microorganisms. 2019; 7(3): 67, CrossRef.
Campbell-Thompson M, Fu A, Kaddis JS, Wasserfall C, Schatz DA, Pugliese A, et al. Insulitis and β-cell mass in the natural history of type 1 diabetes. Diabetes. 2016; 65(3): 719-31, CrossRef.
Drexhage HA, Dik WA, Leenen PJ, Versnel MA. The immune pathogenesis of type 1 diabetes: not only thinking outside the cell but also outside the islet and out of the box. Diabetes. 2016; 65(8): 2130-3, CrossRef.
Zubaidah E, Nuril I. Efek cuka apel dan cuka salak terhadap penurunan glukosa darah dan histopatologi pankreas Tikus Wistar diabetes. Jurnal Kedokteran Brawijaya. 2015; 28(4): 297-301, CrossRef.
Negara BFSP, Choi JS. Bifidobacterium lactis inhibits iNOS expression in LPS-stimulated RAW 264.7 macrophages. Indones Biomed J. 2022; 14(2): 199-205, CrossRef.
Rifaai RA, El-Tahawy NF, Saber EA, Ahmed R. Effect of quercetin on the endocrine pancreas of the experimentally induced diabetes in male albino rats: a histological and immunohistochemical study. J Diabetes Metab. 2012; 3: 3, CrossRef.
Li H, Zhang L, Chen L, Zhu Q, Wang W, Qiao J. Lactobacillus acidophilus alleviates the inflammatory response to enterotoxigenic Escherichia coli K88 via inhibition of the NF-κB and p38 mitogen-activated protein kinase signaling pathways in piglets. BMC Microbiol. 2016; 16(1): 273, CrossRef.
Ventura-Oliveira D, Vilella CA, Zanin ME, Castro GM, Moreira Filho DC, Zollner RL. Kinetics of TNF-alpha and IFN-gamma mRNA expression in islets and spleen of NOD mice. Braz J Med Biol Res. 2002; 35(11): 1347-55, CrossRef.
Mandrup-Poulsen T, Pickersgill L, Donath MY. Blockade of interleukin 1 in type 1 diabetes mellitus. Nat Rev Endocrinol. 2010; 6(3): 158-66, CrossRef.
Rahman MN, Diantini A, Fattah M, Barliana MI. Nutritional biomarkers for predicting pancreatic beta cell failure in central obesity. Indones Biomed J. 2021; 13(1): 19-26, CrossRef.
Valladares R, Sankar D, Li N, Williams E, Lai KK, Abdelgeliel AS, et al. Lactobacillus johnsonii N6.2 mitigates the development of type 1 diabetes in BB-DP rats. PLOS ONE. 2010; 5: 1-9, CrossRef.
Kartikadewi A, Prasetyo A, Budipradigdo L, Nugroho H, Tjahjono K, Lelono A. Artemisia annua leaf extract increases GLUT-4 expression in type 2 diabetes mellitus rat. Indones Biomed J. 2019; 11(1): 78-84, CrossRef.
DOI: https://doi.org/10.18585/inabj.v14i4.2047
Copyright (c) 2022 The Prodia Education and Research Institute
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Indexed by:
The Prodia Education and Research Institute
